Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Matthieu Delaye1, Astrid Lièvre2, Cindy Neuzillet1

  • 1Institut Curie, département d'oncologie médicale. Université Versailles-Saint-Quentin (UVSQ). Saint-Cloud, France; Association pour l'étude des Cancers et Affections des voies Biliaires (ACABi), Paris, France.

Bulletin Du Cancer
|December 19, 2022
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study.

medRxiv : the preprint server for health sciences·2026
Same author

Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspective.

Cancer treatment reviews·2026
Same author

Improving cancer care while reducing its carbon footprint: GHG-mitigating strategies highlighted at ESMO 2025.

BJC reports·2026
Same author

Predicting survival of patients treated with antibody-drug conjugates in early-phase clinical trials using AI-quantified 3D body composition on CT scans.

Frontiers in oncology·2026
Same author

Evaluation of renal exclusion criteria in early phase oncology trials: A call for modernization.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles

Immunotherapy offers a new treatment for advanced biliary tract cancers (BTC), but its benefits are modest. Identifying predictive markers is crucial for improving patient outcomes in this rare cancer.

Area of Science:

  • Oncology
  • Immunology

Context:

  • Biliary tract cancers (BTC) are rare and aggressive malignancies with poor prognoses.
  • Current standard treatments involve chemotherapy, offering limited efficacy and duration of benefit.

Purpose:

  • To review the current status and future directions of immunotherapy for advanced BTC.
  • To discuss the rationale, existing data, and challenges in applying immunotherapy to BTC.

Summary:

  • Immunotherapy represents a novel therapeutic strategy for advanced BTC.
  • However, its efficacy in BTC appears less pronounced compared to other cancers, necessitating further research.
  • Key challenges include identifying reliable biomarkers to predict treatment response.

Impact:

Keywords:
Biliary tract cancerBiomarkersBiomarqueursCancers des voiesImmunotherapyImmunothérapiebiliaires

Related Experiment Videos

  • This review aims to guide future research and clinical strategies for optimizing immunotherapy in BTC.
  • Understanding response predictors will be vital for personalizing treatment and improving survival rates for patients with advanced BTC.